How many 8-K filings has Xeris Biopharma Holdings, Inc. filed?

Xeris Biopharma Holdings, Inc. (XERS) has 11 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Xeris Biopharma Holdings, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Xeris Biopharma Holdings, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Xeris Biopharma Holdings, Inc. (XERS) — 8-K Filings

All 8-K filings from Xeris Biopharma Holdings, Inc.. Browse 11 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (11)

Xeris Biopharma Files 8-K — Dec 1, 2025 Risk: low
Xeris Biopharma Holdings, Inc. filed an 8-K on December 1, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD
Xeris Biopharma Holdings Files 8-K on Shareholder Votes — Jun 4, 2025 Risk: low
Xeris Biopharma Holdings, Inc. filed an 8-K on June 4, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
Xeris Biopharma Files 8-K Report — Jun 3, 2025 Risk: low
On June 3, 2025, Xeris Biopharma Holdings, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits.
Xeris Biopharma Files 8-K on Executive Changes — Mar 28, 2025 Risk: medium
Xeris Biopharma Holdings, Inc. filed an 8-K on March 28, 2025, reporting on the departure of directors or certain officers, election of directors, appointment o
Xeris Biopharma Files 8-K: Director Changes & Compensation — Feb 24, 2025 Risk: medium
Xeris Biopharma Holdings, Inc. filed an 8-K on February 24, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangeme
Xeris Biopharma Files 8-K on Financials — Jan 10, 2025 Risk: low
Xeris Biopharma Holdings, Inc. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing includes financial s
Xeris Biopharma Files 8-K on Financials — Nov 8, 2024 Risk: low
On November 8, 2024, Xeris Biopharma Holdings, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
Xeris Biopharma Names New Directors, CEO Gets New Contract — Aug 2, 2024 Risk: medium
On August 1, 2024, Xeris Biopharma Holdings, Inc. announced changes in its board of directors and executive compensation. The company elected two new directors,
Xeris Biopharma CFO Departs; Q2 Revenue Previewed — Jul 8, 2024 Risk: medium
Xeris Biopharma Holdings, Inc. announced on July 7, 2024, the departure of its Chief Financial Officer, Richard King, effective July 12, 2024. The company also
Xeris Biopharma Announces Board Changes and Compensation Updates — Jun 5, 2024 Risk: medium
On June 5, 2024, Xeris Biopharma Holdings, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes
Xeris Biopharma Files 8-K on Operations & Financials — Jan 4, 2024
Xeris Biopharma Holdings, Inc. filed an 8-K on January 4, 2024, to report on its results of operations and financial condition. This filing, under SEC File Numb

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX